Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a SAT-3247 dose comparison study in ambulatory Duchenne muscular dystrophy
2025-522522-13-01Phase 2Authorised
- Sponsor
- Satellos Bioscience Inc.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of forazapadin in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Satellos Bioscience Inc. Primary endpoints: Change from baseline in muscle force by dynamometry at Week 12, Incidence, temporal profile, and severity of treatment-emergent adverse events and 4 more. Planned start Apr 2026; status: authorised.
02
Drugs
forazapadin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2025-522522-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522522-13-01.